Tuesday, March 31, 2015

"Cancer biomarker testing is now a mainstay of 21st century pathology practice..."

Philip T. CagleMD; Randall J. OlsenMD, PhD; Bryce P. PortierMD, PhD; Hidehiro TakeiMD; David W. BernardMD, PhD
From the Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas


"Cancer biomarker testing is now a mainstay of 21st century pathology practice, embracing the pathologist’s role in patient selection for specific targeted therapies. Pathologists, oncologists, and others require direction in adapting to this new ever-evolving paradigm."

No comments:

Post a Comment